Opportunity
Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor. ENAMINE US INC
Response due
September 19, 2026
- Agency
- National Institutes of Health Olao
- Estimated value
- Not stated
The Section on Medicinal Chemistry (SMC) develops new molecular entities with implications in improving health and treatment for various metabolic and alcohol associated diseases. To assess the translational potential of novel molecular entities, which would allow us to make decisions to proceed the compounds for further development we utilize multiple derisking assays. These assays comprise of both cell-based (in vitro) testing and then eventually in mice to assess pharmacokinetic parameters to see if the drug is orally available. Request to procure Chemical Reagent (Assay) Development & Laboratory Testing Service SMC to produce grouped ADME assays and perform a Pharmacokinetic study in C57BL6 mice. By including the Caco-2 Permeability Assay in our ADME evaluation it'll accurately predict the oral absorption potential of our compounds. This well-established in vitro model closely mimics the human intestinal epithelium, providing critical insights into a compound’s passive diffusion, active transport, and efflux processes, such as those mediated by P-glycoprotein (P-gp). The data generated from this assay are vital for informing structure-activity relationship (SAR) optimization, improving compound permeability, and reducing transporter-related liabilities that could hinder bioavailability
Key dates
- Posted
- September 10, 2026
- Response due
- September 19, 2026
Who is this buyer
Organization
Buying history
- Records263 total
- Opportunities / awards10 / 20
- Value range$0 – $30,482,226
- ActiveJuly 15, 2026 – October 26, 2026
What they buy
- Clinical (251)
- Administrative (12)
Set-asides used
- No Set aside used (68)
- Small Business Set Aside - Total (14)
Who holds their work today
- EAGLE HEALTH, LLC1 win · $30,482,226 · last February 1, 2020
- LC INDUSTRIES INC1 win · $286,880 · last February 13, 2026
Also open from this buyer
- Clinical Research Support and Collaboration for NHGRI ProtocolsDue November 13, 2026 · Clinical
- NOI - 4D-Nucleofector Core Unit and X UnitDue November 5, 2026 · Clinical
- Reagents and consumables for Roche immunostainersDue October 28, 2026 · Clinical
- Combines Synopsis Solicitation- Automated SpatialDue November 5, 2026 · Clinical
View source document →
Source link on sam.gov.
Source record
- Buyer type
- Federal
- Jurisdiction
- Federal (US)
- Category
- Clinical
- Set-aside
- No Set aside used
- NAICS
- 424690
- PSC
- 6505